{"id":"test-4","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108771","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"No information is available on the mechanism of action of TEST 4.","oneSentence":"TEST 4 is a drug that has not been found in available data.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:38:09.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT07156227","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-22","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05377424","phase":"PHASE1, PHASE2","title":"Adenosine 2A Receptor Antagonism and AIH in ALS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-06-21","conditions":"ALS","enrollment":40},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT05112601","phase":"PHASE2","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-02","conditions":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":81},{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT05842122","phase":"NA","title":"Pharmacy-based PrEP Delivery in Kenya","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-06-20","conditions":"Hiv","enrollment":5808},{"nctId":"NCT05064293","phase":"NA","title":"Assisted Identification and Navigation of Early Mental Health Symptoms in Children","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-09-07","conditions":"Adolescent Behavior, Mental Health Issue","enrollment":358},{"nctId":"NCT04052555","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-24","conditions":"Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma","enrollment":42},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT06980038","phase":"PHASE2","title":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-21","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":152},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT07495007","phase":"PHASE1","title":"An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection","status":"COMPLETED","sponsor":"Zi Diligence Biocenter","startDate":"2025-11-10","conditions":"Bioequivalance, Post-menopause","enrollment":26},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT07313540","phase":"NA","title":"Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-10","conditions":"Aging, Dementia, Cognitive Decline","enrollment":40},{"nctId":"NCT06979960","phase":"NA","title":"The Effect of Face-to-Face and Online Training on Cancer Screening on Women's Knowledge, Attıtude and Shyness","status":"COMPLETED","sponsor":"Inonu University","startDate":"2024-09-01","conditions":"Being Literate, Not Having Any Cognitive, Visual or Orthopedic Disabilities, Being Between the Ages of 50-65","enrollment":68},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT06747221","phase":"NA","title":"Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya","status":"NOT_YET_RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2026-06-01","conditions":"HIV","enrollment":184},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT06888323","phase":"PHASE1","title":"Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-27","conditions":"Refractory Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT06917911","phase":"PHASE2","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-18","conditions":"Core Binding Factor Acute Myeloid Leukemia","enrollment":162},{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":156},{"nctId":"NCT05713799","phase":"PHASE2","title":"Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Insulin Resistance, Obesity","enrollment":60},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT07273019","phase":"NA","title":"Tongue Muscular Assessment in Children With Sleep Disordered Breathing","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-03-26","conditions":"Obstructive Sleep Apnea","enrollment":78},{"nctId":"NCT05687136","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-07","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT04595747","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-03","conditions":"Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor","enrollment":48},{"nctId":"NCT04145115","phase":"PHASE2","title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-24","conditions":"Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype","enrollment":37},{"nctId":"NCT07495917","phase":"NA","title":"Tetris Intervention Following Subliminal Reactivation for Intrusive Memories","status":"NOT_YET_RECRUITING","sponsor":"Shaanxi Normal University","startDate":"2026-03-27","conditions":"Post-traumatic Stress Disorder (PTSD), Intrusive Memories of Traumatic Event(s)","enrollment":123},{"nctId":"NCT06811116","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-17","conditions":"Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8","enrollment":92},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT04963153","phase":"PHASE1","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-07","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":24},{"nctId":"NCT07169630","phase":"PHASE1","title":"PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2026-04-01","conditions":"Alzheimer s Disease, Mild Cognitive Impairment, Healthy","enrollment":90},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06015880","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-20","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT07169617","phase":"PHASE2","title":"Testing the SurVaxM Vaccine for Lung Cancer Prevention","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-25","conditions":"Lung Carcinoma","enrollment":80},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT03816319","phase":"PHASE1","title":"TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-12","conditions":"Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":42},{"nctId":"NCT06223542","phase":"PHASE1","title":"Studying TAK-243 in Patients With Advanced Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-24","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma","enrollment":95},{"nctId":"NCT03502733","phase":"PHASE1","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-14","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":64},{"nctId":"NCT03783000","phase":"PHASE1","title":"A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-01-15","conditions":"Healthy","enrollment":6},{"nctId":"NCT02595944","phase":"PHASE3","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":903},{"nctId":"NCT05473429","phase":"NA","title":"Characterization of Nociception Phenotype in Individuals With Intellectual Disability","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2026-04-01","conditions":"Intellectual Disability","enrollment":215},{"nctId":"NCT05740982","phase":"PHASE2","title":"A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-22","conditions":"Monkeypox","enrollment":450},{"nctId":"NCT04345913","phase":"PHASE1, PHASE2","title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-01","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT04172532","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-11","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":92},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT04140721","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-31","conditions":"Postural Tachycardia Syndrome","enrollment":48},{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT05165810","phase":"NA","title":"Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-09","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT03983824","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-05","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT04269902","phase":"PHASE3","title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-02","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":247},{"nctId":"NCT03140865","phase":"","title":"Wake Forest Alzheimer's Disease Clinical Core","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2014-01","conditions":"Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State","enrollment":850},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT06930170","phase":"NA","title":"Evaluation of Cochlear Implantation in Unilateral or Asymmetric Hearing Loss in Children.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-03-09","conditions":"Unilateral Hearing Loss, Asymmetric Hearing Loss","enrollment":36},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155},{"nctId":"NCT05691491","phase":"PHASE1, PHASE2","title":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-28","conditions":"Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm","enrollment":58},{"nctId":"NCT04034927","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":"Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor","enrollment":61},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":"Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma","enrollment":314},{"nctId":"NCT06568172","phase":"PHASE3","title":"Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-18","conditions":"Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma","enrollment":420},{"nctId":"NCT03327805","phase":"NA","title":"Short Term Choline and Cardiovascular Health","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2019-05-08","conditions":"Cardiovascular Risk Factor","enrollment":20},{"nctId":"NCT04750954","phase":"PHASE1","title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-22","conditions":"Neuroendocrine Neoplasm","enrollment":29},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT02339571","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-23","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":600},{"nctId":"NCT07359365","phase":"NA","title":"The Effect of Breathing Exercises on Compassion Fatigue and Work Tress Among Emergency Department Nurses","status":"NOT_YET_RECRUITING","sponsor":"Çanakkale Onsekiz Mart University","startDate":"2026-04-01","conditions":"Work Stress","enrollment":64},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT06568484","phase":"PHASE2, PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":"Tuberculosis, Latent","enrollment":2530},{"nctId":"NCT07498387","phase":"NA","title":"Management of Catatonic Features in Adolescents With Profound Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Autism Spectrum Disorder, Catatonia","enrollment":30},{"nctId":"NCT00310180","phase":"PHASE3","title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04-07","conditions":"Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7","enrollment":10273},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":"Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT03604978","phase":"PHASE1, PHASE2","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-17","conditions":"Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma","enrollment":38},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT05419011","phase":"PHASE2","title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-08","conditions":"Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome","enrollment":186},{"nctId":"NCT05886049","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-20","conditions":"Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation","enrollment":28},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":878},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":46},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1329,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TEST 4","genericName":"TEST 4","companyName":"Center for Health Sciences, Serbia","companyId":"center-for-health-sciences-serbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}